Add to a list

Inactive Instrument

ATHENEXPAR Stock

ATNX

US04685N2027

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Analysts' recommendations: ATHENEXPAR

23-03-21	Ladenburg Thalmann Downgrades Athenex to Neutral From Buy	MT
22-04-13	Truist Securities Adjusts Athenex's Price Target to $3 from $6, Keeps Hold Rating	MT
22-03-17	SVB Leerink Adjusts Athenex's Price Target to $3 from $2, Keeps Market Perform Rating	MT
22-03-17	RBC Capital Adjusts Price Target on Athenex to $4 From $5, Maintains Outperform Rating, Assigns Speculative Risk Qualifier	MT
21-10-12	ATHENEX : RBC Cuts Price Target on Athenex to $5 From $8 Amid Discontinuation of Oraxol in Metastatic Breast Cancer; Outperform Kept	MT

More recommendations

Managers and Directors: ATHENEXPAR

Manager	Title	Age	Since
Yiu Nam Lau CEO	Chief Executive Officer	65	2010-12-31
Jacqueline Li PRN	Corporate Officer/Principal	-	2016-12-31
Nick Campbell PRN	Corporate Officer/Principal	-	2023-04-18

Director	Title	Age	Since
Yiu Nam Lau CHM	Chairman	65	2003-10-31
Jinn Wu BRD	Director/Board Member	77	2007-03-31
Manson Fok BRD	Director/Board Member	69	2015-05-31

More insiders

Athenex, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of next-generation products for the treatment of cancer. The Company's segments include Oncology Innovation Platform and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Commercial Platform is focused on the sales and marketing of its specialty drugs and the market development of its drugs. Its clinical pipeline in the Oncology Innovation Platform is derived from its technologies: Cell Therapy, based on natural killer T (NKT) cells, and Orascovery, based on a P-glycoprotein pump inhibitor. Its product candidates include KUR-501, KUR-502, and KUR-503. KUR-501 is an autologous product in which NKT cells are engineered with a chimeric antigen receptor (CAR) targeting disialoganglioside (GD2). KUR-503 is an allogeneic product in which NKT cells are engineered with a CAR targeting glypican-3.

Employees

275

Sector

More about the company

23-09-22	Athenex, Inc. Went Out of Business	CI
23-09-18	First Motion for Exclusivity Period Extension Approved For Athenex, Inc.	CI
23-09-12	Liquidation Plan Approved for Athenex, Inc.	CI
23-09-08	First Motion for Exclusivity Period Extension Filed by Athenex, Inc.	CI
23-08-17	Athenex, Inc. Announces the Separation of Joe Annoni as Chief Financial Officer	CI
23-08-17	Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer	CI
23-08-09	Illumina cuts annual profit forecast as biotech funding woes linger	RE
23-08-09	Illumina cuts annual profit forecast	RE
23-08-01	Modified Disclosure Statement Approved on Interim Basis for Athenex, Inc.	CI
23-08-01	Motion for Asset Sale Approved for Athenex, Inc.	CI
23-07-26	Combined Liquidation Plan and Disclosure Statement Filed by Athenex, Inc.	CI
23-07-25	Danaher cuts forecast for annual sales growth as biotech clients face funding crunch	RE
23-06-27	Motion for Asset Sale Approved for Athenex, Inc.	CI

23-05-22	ATHENEX, INC. : Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Costs Associated with Exit or Disposal Activities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
23-05-14	Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process	AQ
23-05-03	ATHENEX, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-04-25	ATHENEX, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
23-03-31	ATHENEX, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-05-04	Timothy Devere Cook	Free	See Remarks	368	0.0042%
23-05-04	Avalon BioMedical (Management) Ltd.	Other	Company	0	0%
23-05-04	Rudolf Kwan	Free	EVP, Chief Medical Officer	3,603	0.0416%

ATHENEXPAR Stock

Stocks

ATNX

US04685N2027

Latest news : ATHENEXPAR

Analysts' recommendations: ATHENEXPAR

Press Releases: ATHENEXPAR

Managers and Directors: ATHENEXPAR

Latest insider transactions

Company Profile